Accès ouvert
2026
article
OpenAlex
Gang‐Qing Yao, Meiling Zhu, Karl Insogna
Single daily doses of parathyroid hormone (PTH) are an established anabolic therapy for osteoporosis. The actions of PTH in bone are modulated by interactions between osteoblasts and osteoclasts. Colony-stimulating factor 1 (CSF1) exists in both soluble (sCSF1) and membrane-bound (mCSF1) isoforms, with …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Luisa Bernacet, Sean C. Peden, Dieter M. Lindskog, Gabriela Spilberg et autres
Abstract Disclosure: L. Bernacet: None. S. Peden: None. D.M. Lindskog: None. G. Spilberg: None. C. Bergwitz: Alexion Pharmaceuticals, Inc., Sanofi. K.L. Insogna: None. K. Mekala: None. Tumor-induced osteomalacia (TIO) is a rare paraneoplastic process characterized by osteomalacia from hypophosphatemia due to renal …
us
(code pays fourni par la source)
2025
article
OpenAlex
Rucha Anant Patki, Thomas O. Carpenter, Keerti Murari, Stephen Parziale et autres
Fractures and pseudofractures cause considerable morbidity in adults with X-linked hypophosphatemia (XLH). They frequently occur in cortically-enriched bones of the lower extremities. Burosumab, a neutralizing antibody to FGF23, heals fractures in adults with XLH, presumably by healing osteomalacia. Histomorphometry has documented healing …
us, es
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jessica Bihuniak, Christine Simpson, Rebecca Sullivan, Josephine Dudzik et autres
Background/Objectives: Studies have reported an increased risk of type 2 diabetes among people with higher protein intake. Moreover, branched-chain amino acids (BCAA) are reported to be positively associated with insulin resistance (IR). However, it is not understood whether elevated levels of BCAA …
us
(code pays fourni par la source)
Accès ouvert
2025
erratum
OpenAlex
Gang‐Qing Yao, Meiling Zhu, Karl Insogna
us
(code pays fourni par la source)
Accès ouvert
2024
erratum
OpenAlex
Gang‐Qing Yao, Meiling Zhu, Karl Insogna
us
(code pays fourni par la source)
2024
article
OpenAlex
Gang‐Qing Yao, Meiling Zhu, Karl Insogna
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Krina Mehta, Nathalie H. Gosselin, Karl Insogna, Olivier Barrière et autres
Burosumab is indicated for treatment of a rare bone disease, X-linked hypophosphatemia (XLH). The aim of this analysis was to evaluate the relationship between a treatment response biomarker and patient-reported outcomes (PROs). Longitudinal data for PROs were obtained from adults with XLH …
us, gb
(code pays fourni par la source)
2024
article
OpenAlex
Meiling Zhu, Caroline J. Zeiss, Mark W. Hamrick, Robert S. Weinstein et autres
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Gang Yao, Meiling Zhu, Karl Insogna
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Karl Insogna, Rebecca Sullivan, Stephen Parziale, Yanhong Deng et autres
CONTEXT: In clinical trials, burosumab ameliorates symptoms of pain, fatigue, and stiffness and improves performance on certain muscle function studies in patients with X-linked hypophosphatemia (XLH). OBJECTIVE: This work aimed to determine if burosumab increases adenosine triphosphate (ATP) synthesis in skeletal muscle …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Christine Simpson, Anna Maria Santoro, Thomas O. Carpenter, Yanhong Deng et autres
Individuals with X-linked hypophosphatemia (XLH) are at greater risk for being overweight or obese. Whether there are underlying metabolic abnormalities that put patients with XLH at greater risk for excessive weight gain is largely unknown. Lipocalin-2 (LCN2) has recently received attention as …
us
(code pays fourni par la source)